Microdosing

As demand for GLP-1 drugs like Ozempic and Wegovy soars, a parallel market for compounded versions has emerged — one that’s largely unregulated and increasingly risky. This episode examines how gaps in oversight, aggressive marketing, and blurred lines between compounding and manufacturing expose patients to safety concerns and strain the health system. We explore why compounded GLP-1s are more than a niche issue, highlighting how they fit a recurring pattern where regulation lags behind fast-moving markets.

Medicaid and Medicare Advantage may seem like programs for specific groups, but the choices made in these public plans ripple across the entire insurance system. This episode explores how coverage churn, capped benefits, and financing reforms in public programs ultimately shape commercial premiums, provider networks, and patient access for everyone. We unpack why what starts in Medicaid and Medicare Advantage rarely stays there, and how those shifts end up reshaping all of our coverage.

Primary care consolidation is changing how patients experience — and pay for — everyday healthcare. This episode examines how ownership, pricing, and place intersect to drive up costs, with research from The Journal of the American Medical Association showing that hospital and private equity–affiliated practices charge more without delivering clear quality gains. We unpack what this hidden shift means for patients, insurers, and the future of affordable primary care.

Firearms have become the leading cause of death among U.S. children and teens, yet unlike cars, toys, or even e-cigarettes, they remain exempt from basic consumer safety regulation. This episode explores the public health and economic costs of treating guns as constitutionally protected products rather than consumer goods, drawing on recent research and commentaries from The Journal of the American Medical Association (JAMA) and JAMA Health Forum. We highlight what a true public health approach could look like (from child locks to smart-gun technology) and why closing this regulatory gap could save lives and reduce systemwide costs.

Patients are no longer entering care through the doors traditional health systems control. This episode explores how retail brands, pharma platforms, and digital experiences are becoming the new “front doors,” transferring trust and reshaping where care journeys begin. We look at what this shift means for partnerships, brand equity, and how healthcare organizations must adapt to stay relevant at the first point of engagement.

Rising clashes between hospitals and insurers are exposing outdated fee-for-service infrastructure. As payer–provider clashes surge, healthcare infrastructure is under pressure. We unpack what’s fueling these disputes, how they impact patients, and why flexible platforms may be the key to moving forward.

From weight loss buzz to healthcare infrastructure, GLP-1 drugs started as diabetes treatments but are now reshaping weight loss, care delivery, and consumer markets. In this episode, we explore how they have become more than medicine, driving new business models, digital access points, and patient expectations, featuring insights from leaders across health plans, startups, and strategy firms.

Microdosing is adjusting its format. This episode gives listeners a sneak peek at how Microdosing will be adopting a report-based, written-format-first approach to content. And be moving deeper into the 21st century by having those reports converted to audio podcasts using our new AI-based narrator, Mavis.

We interviewed a group of terrific product leaders during this time. Looking back, here are a few of our observations.

Product Management guru Alex Moseman discusses his journey in leading digital product innovation, emphasizing problem-solving over product-centric approaches. He talks about transition challenges in product management, embracing failure for innovation, and the power of asking insightful questions for effective management.